We are deeply honoured to share that DCVMN International has been awarded the 2026 IVI-SK Bioscience Park MahnHoon Award, presented by the International Vaccine Institute (IVI) and SK bioscience during a grand ceremony in Seoul, South Korea on April 23rd. DCVMN CEO Rajinder Suri accepted the award from Dr. Jerome Kim, Director General IVI and Dr. Jaeyong Ahn, President & CEO, SK bioscience, on behalf of the network, alongside fellow awardee Professor Emirtus Walter Orenstein, former Director of the United States National Immunization Program and co-author of the legendary book “Vaccines.”
The IVI-SK Bioscience Park MahnHoon Award is one of the most prestigious recognitions in the global vaccine field, established to honour individuals and organizations whose contributions have made a meaningful and lasting impact on global vaccine access and public health. Winning this coveted award is a matter of great honour for DCVMN.
DCVMN’s selection for this award recognises the network’s extraordinary contributions to the innovation, development, manufacturing, and supply of life-saving vaccines, particularly for LMICs and its exemplary leadership in expanding global vaccine access, fostering collaboration, driving innovation, and strengthening regulatory capacity. Most importantly, it is a recognition that these collective efforts have saved millions of lives and meaningfully advanced vaccine equity and sustainability in global health.
This honour belongs to every one of our member companies, working group contributors, partners, and collaborators who have made DCVMN’s mission a reality. It is a reflection of what is possible when developing-country manufacturers are supported, heard, and empowered to lead!
The day that followed was equally meaningful, Rajinder held a full day of meetings, facility tours, and discussions with IVI, one of DCVMN’s longstanding partners. IVI is an independent international organization, dedicated to public health, headquartered in Seoul dedicated to developing, and delivering safe, effective, and affordable vaccines for the world’s most vulnerable populations. The conversations focused on strengthening and expanding the collaboration between our two organizations, exploring new opportunities to jointly advance vaccine access, capacity-building, and innovation in LMICs.
At DCVMN, we believe that progress in global health is built on bridges: between regions, between institutions, and between ambition and action. This award reaffirms our commitment to keep building them!
Learn more: https://www.skbioscience.com/en/news/news_01_01?mode=2&id=348&page=1
